BOSTON, Mass. — Corsera Health announced it has raised $80 million in an oversubscribed Series A financing and has initiated dosing in its first clinical trial, marking a key milestone for the cardiovascular prevention-focused company.
The Series A financing was co-led by Forbion and Population Health Partners, with participation from additional investors, including Corsera co-founder and co-chief executive officer John Maraganore, Ph.D. As part of the financing, Marco Boorsma, Ph.D., general partner at Forbion, will join Corsera Health’s board of directors. Proceeds from the round will support the company’s strategy to extend healthspan by enabling individuals to better understand and reduce their risk of atherosclerotic cardiovascular disease.
Alongside the financing, Corsera announced the initiation of dosing in a Phase 1 clinical trial of COR-1004, a novel subcutaneously administered small interfering RNA targeting PCSK9.
“At Corsera, we are motivated by a bold vision: a world without cardiovascular disease,” said Clive Meanwell, M.D., co-founder and co-chief executive officer of Corsera Health and managing partner of Population Health Partners. “We are making strong progress toward a future in which preventive care enables people to live longer, healthier lives, and the initiation of our first clinical trial marks an important milestone on that journey.”
“With this financing and the start of our first clinical trial, we are entering a pivotal next phase for the company,” said John Maraganore, Ph.D., co-founder and co-chief executive officer of Corsera Health. “By combining AI-enabled prediction of lifetime ASCVD risk with preventive RNAi medicines, Corsera has the potential to change the trajectory of cardiovascular disease, enabling earlier intervention and broad access to prevention at a population scale.”
The funding will support advancement of Corsera Health’s preventive RNAi medicine program, which targets two primary drivers of cardiovascular disease: low-density lipoprotein cholesterol and blood pressure. The company’s approach uses RNAi to silence PCSK9 to lower LDL-C and angiotensinogen to reduce blood pressure. Designed for once-annual administration, the preventive medicines are intended to support population-scale reach, ease of use, and broad access.
The financing will also fund continued development of Klotho, Corsera Health’s proprietary AI-enabled precision health platform designed to predict lifetime cardiovascular disease risk and quantify the potential benefit of lowering LDL-C and blood pressure to extend cardiovascular healthspan.
“Corsera Health exemplifies the kind of bold, science-driven innovation that Forbion aims to support and scale,” said Marco Boorsma, Ph.D., general partner at Forbion. “The company’s integrated approach, combining durable RNAi therapeutics with advanced predictive technology, has the potential to fundamentally shift cardiovascular care from late intervention to true prevention.”
The Phase 1 clinical trial of COR-1004 is designed to evaluate safety and tolerability, with secondary objectives including assessment of clinical activity through reductions in plasma PCSK9 levels and serum LDL-C, as well as characterization of pharmacokinetics. Corsera expects to report initial proof-of-concept data in 2026.
COR-1004 is the first of two components in the company’s lead preventive RNAi medicine program. A Phase 1 clinical trial of COR-2003, a subcutaneously administered siRNA targeting angiotensinogen, is expected to begin in mid-2026.
